Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Milk gangliosides are a **non-single-entity mixture of sialylated glycosphingolipids** naturally enriched in the milk fat globule membrane, with **GM3 and GD3** as the principal species reported in bovine and human milk. In the provided literature, they are used primarily as a **nutritional bioactive ingredient / nutraceutical** rather than a conventional pharmaceutical, most often by **oral dietary supplementation**. Their proposed mechanisms are not target-specific in the classic drug sense; instead, they appear to act through **membrane glycan-mediated host-pathogen decoy effects**, **modulation of gut barrier integrity and permeability**, **effects on intestinal microbiota and immune development**, and possible **support of neurodevelopment**. Public-source evidence includes multiple peer-reviewed publications describing dietary milk gangliosides in preclinical models, including work suggesting benefit in **GM3 synthase deficiency** models and in intestinal barrier biology, but there is no clear evidence in the supplied material of a uniquely branded, sponsor-developed pharmaceutical product based on this exact substance mixture.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on milk gangliosides.